MS4Omics

MS4Omics expands its service capacity in large-scale proteomics, proteogenomics, advanced mass spectrometry imaging spanning from ex vivo to in vivo settings, multiplexing techniques, spatial omics to single-cell analyses, and MS structural elucidation through interactomic approaches such as BioID and Cross-Link MS.

In addition, MS4Omics boasts extensive experience in handling clinical samples, particularly those from large cohorts. Notably, our proficiency in analyzing extracellular vesicles (EVs) derived from various biological fluids—such as plasma, urine, cerebrospinal fluid (CSF), and amniotic fluid—provides valuable insights into disease mechanisms and biomarker discovery in clinical settings.

MS4Omics is uniquely positioned to address a wide spectrum of scientific inquiries, ranging from fundamental protein identification in fully sequenced organisms to intricate analyses involving quantification of variations, dynamics of post-translational modifications, identification of proteins in non-sequenced genomes, interactomics, and MS imaging. We offer comprehensive support spanning from meticulous sample preparation to sophisticated data processing.

MS4Omics can treat from the simplest questions (identification of proteins from fully sequenced organisms) as the most complex ones (quantification of variations, dynamics of post-translational modifications, identification of proteins of non-sequenced genomes, interactomics, MS imaging...) since its expertise is not limited to the analytical part but ranges from the sample preparation to the data processing.

consult our PDF document for more information

MS4Omics will expand the capacity of ProFI services through specific services

Biological and clinical sample preparation independently the sample type (cells, tissue, EVs, organoids) and conservation/age (Frozen, Fixed, Formalin Fixed and Paraffin Embedded (FFPE)
MS Imaging (MALDI-MSI, DESI-MSI, SpiderMass) of peptides, proteins, metabolites, and lipids form fresh frozen or FFPE samples (retrospective cohorts), or exogenous compounds (drugs, xenobiotics); Drug screening and quantification from 2D and 3D cell cultures and drug monitoring by MALDI MSI at high throughput and/or high resolution.
Specific data processing for the identification of alternative proteins issued from non-coding alternative ORF (including non-coding regions) or from not sequenced species.